Acumen Pharmaceuticals (ABOS) EV/FCF: History & Chart

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T17:05:28.356Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:05:28.356Z.

Quote observation: 2026-10-06T17:05:12.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 147,344,304
Total debt · period ending 2026-06-30: 31,569,000
Cash · period ending 2026-06-30: 59,443,000
TTM free cash flow · period ending 2026-06-30: -91,788,000

FMP input reference: 5d81df243028a463df18dadfb6b81954a95dec5b5738e9798e17a16434fd93e0

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

ABOS EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

ABOS Competitors' EV/FCF Ratio

ABOS

Acumen Pharmaceuticals, Inc.

Current

Market Cap

$147.34M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVXL

Anavex Life Sciences Corp.

vs ABOS

Market Cap

$146.42M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LFMDP

LifeMD, Inc.

vs ABOS

Market Cap

$148.31M

EV/FCF Ratio

N/A

TTM Avg

175.94x

3Y Avg

1237.69x

5Y Avg

1237.69x

NGEN

NervGen Pharma Corp. Common stock

vs ABOS

Market Cap

$149.18M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KRSA

Korsana Biosciences, Inc.

vs ABOS

Market Cap

$144.23M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NYXH

Nyxoah S.A.

vs ABOS

Market Cap

$144.10M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STRO

Sutro Biopharma, Inc.

vs ABOS

Market Cap

$142.55M

EV/FCF Ratio

N/A

TTM Avg

31.12x

3Y Avg

31.12x

5Y Avg

31.12x

CRDL

Cardiol Therapeutics Inc.

vs ABOS

Market Cap

$151.58M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDXS

Codexis, Inc.

vs ABOS

Market Cap

$151.15M

EV/FCF Ratio

N/A

TTM Avg

40.01x

3Y Avg

40.01x

5Y Avg

40.01x

IMRX

Immuneering Corporation

vs ABOS

Market Cap

$141.94M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Acumen Pharmaceuticals, Inc. (ABOS)	$147.34M	N/A	N/A	N/A	N/A
Anavex Life Sciences Corp. (AVXL)vs ›	$146.42M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMDP)vs ›	$148.31M	N/A	175.94x	1237.69x	1237.69x
NervGen Pharma Corp. Common stock (NGEN)vs ›	$149.18M	N/A	N/A	N/A	N/A
Korsana Biosciences, Inc. (KRSA)vs ›	$144.23M	N/A	N/A	N/A	N/A
Nyxoah S.A. (NYXH)vs ›	$144.10M	N/A	N/A	N/A	N/A
Sutro Biopharma, Inc. (STRO)vs ›	$142.55M	N/A	31.12x	31.12x	31.12x
Cardiol Therapeutics Inc. (CRDL)vs ›	$151.58M	N/A	N/A	N/A	N/A
Codexis, Inc. (CDXS)vs ›	$151.15M	N/A	40.01x	40.01x	40.01x
Immuneering Corporation (IMRX)vs ›	$141.94M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

ABOS EV/FCF Ratio Metrics

ABOS Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics